MicroRNA Targeting of Oncolytic Viruses for cancer therapy
| Project/Area Number |
22680065
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (A)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Tottori University (2011)
The University of Tokyo (2010) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥14,430,000 (Direct Cost: ¥11,100,000、Indirect Cost: ¥3,330,000)
Fiscal Year 2011: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2010: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
|
|---|
| Keywords | 遺伝子治療 / ウイルス療法 / 癌 / バイオテクノロジー / トランスレーショナルリサーチ |
|---|
| Research Abstract |
Oncolytic viruses are promising therapeutic agents for cancer and are currently under clinical investigation. The virotherapy is novel strategy that viruses infect and replicate within tumor cells, directly lysing and killing them. We have reported that microRNA (miRNA) regulation enables tumor-specific viral replication by altering the expression of a targeted viral gene of an attenuated vaccinia virus vaccine strain LC16m8. We used miRNA-based gene regulation to suppress B5R expression through let-7a, a miRNA that is downregulated in many tumors. The miRNA-regulated vaccinia virus achieved efficient viral replication and oncolysis in cancer cells, but elimination of unwanted replication and associated toxicity in normal cells in vivo.
|
Report
(3 results)
Research Products
(33 results)
-
-
-
-
-
[Journal Article] Enhanced Antitumor Effects of an Engineered Measles Virus Edmonston Strain Expressing the Wild-type N, P, L Genes on Human Renal Cell Carcinoma.2010
Author(s)
Meng X, Nakamura T, Okazaki T, Inoue H, Takahashi A, Miyamoto S, Sakaguchi G, Eto M, Naito S, Takeda M, Yanagi Y andTani K.
-
Journal Title
Molecular Therapy
Volume: 18
Issue: 3
Pages: 544-551
DOI
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
